Monteverde & Associates investigates Alpine Immune Sciences' sale to Vertex Pharmaceuticals for potential shareholder underrepresentation.
Monteverde & Associates PC, a top-ranked M&A Class Action Firm, is investigating Alpine Immune Sciences' (Nasdaq: ALPN) proposed sale to Vertex Pharmaceuticals Inc., where ALPN shareholders are expected to receive $65.00 in cash per share. The firm is seeking information related to this acquisition to determine if shareholders' interests are being adequately represented. For more information, visit MonteverdeLaw.com.
April 18, 2024
3 Articles